Stockreport

Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease

BIOVERATIV INC COMMON  (BIVV) 
Last bioverativ inc common earnings: 2/13 04:15 pm Check Earnings Report
PDF Significant unmet need for a treatment for cold agglutinin disease, a chronic rare blood disease that can result in life-threatening events l [Read more]